{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-086369","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.367700+00:00","generated_at":"2026-05-31T11:37:42.986252+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fennec appoints Jeffrey Hackman as CEO, succeeding Rostislav Raykov","bullets":["Hackman named CEO and director effective August 16, 2024; Raykov steps down after 15 years, remains on board.","Hackman's initial salary $550,000, target bonus 50% of salary, granted 400,000 options vesting over three years.","Raykov enters separation agreement; acceleration of 292,359 options at weighted avg price $7.50; RSUs intact through April 2027.","Hackman brings 30+ years commercial oncology experience; previously led U.S. operations at Sigma Tau, Baxalta, Shire, EUSA Pharma.","Appointment comes as company expands PEDMARK use for cisplatin-induced ototoxicity in pediatric and AYA patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-086369","json":"https://secwatch.observer/filing/0001104659-24-086369.json","markdown":"https://secwatch.observer/filing/0001104659-24-086369.md","text":"https://secwatch.observer/filing/0001104659-24-086369.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924086369/0001104659-24-086369-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924086369/tm2421051d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:37:42.986252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"337fd237b6","claim":"Rostislav Raykov departed as Chief Executive Officer at FENNEC PHARMACEUTICALS INC..","evidence_excerpt":"the Company announced the departure of Rostislav Raykov from his position as the Company’s Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924086369/0001104659-24-086369-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"depart"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"9f5bd062f4","claim":"Jeffrey S. Hackman was appointed as Chief Executive Officer at FENNEC PHARMACEUTICALS INC..","evidence_excerpt":"the Company announced the appointment of Jeffrey S. Hackman as CEO and a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924086369/0001104659-24-086369-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"f5bfdf659d","claim":"Jeffrey S. Hackman was appointed as Director at FENNEC PHARMACEUTICALS INC..","evidence_excerpt":"the Company announced the appointment of Jeffrey S. Hackman as CEO and a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924086369/0001104659-24-086369-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}